Stelara (ustekinumab) / J&J, Mitsubishi Tanabe, BMS - LARVOL DELTA

BG03 Biologics for psoriasis in the older patient: profiles, pitfalls and practicalities. (PubMed, Br J Dermatol) - "Hence, as the prescription of conventional treatments such as methotrexate or ciclosporin can be frustrated by drug interactions or contraindications, the use of biologics could actually be the most appropriate therapeutic avenue to pursue...found ustekinumab or adalimumab to be effective but noted an increased incidence of side-effects (Momose M, Asahina A, Hayashi M et al...However, the presence of psoriatic arthritis in the older group was more likely to have influenced use of the biologic. In conclusion, it is apparent that indications for the prescription of biologics in patients in their seventh decade or more should be the same as in younger cases, but in view of comorbidities and concurrent drug use, there needs to be extra vigilance for side-effects and other complications."

Journal • Review • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases. (PubMed, Br J Dermatol) - "For eczema, therapies such as dupilumab show limited evidence in also treating AA...For instance, baricitinib is licensed for both AD and AA, while upadacitinib is licensed for AD and is currently in phase III trials for AA. Amlitelimab, which targets the OX40 ligand pathway, is currently in phase III clinical trials for atopic dermatitis and in phase II trials for severe AA...In psoriasis, overlapping therapies include ustekinumab, approved for psoriasis and being studied for AA. As for patients with RA, tofacitinib is approved for moderate-to-severe disease and is also utilized in AA. Abatacept is a cytotoxic T lymphocyte-associated protein 4 (CTLA4) immunoglobin costimulatory modulator that attenuates the activation of T cells and is widely used in RA...The Global Registry of Alopecia areata disease Severity and treatment Safety (GRASS) UK is a prospective, multicentre, observational clinical registry designed to create harmonized datasets. These datasets aim to..."

Journal • Review • Alopecia • Atopic Dermatitis • CNS Disorders • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis • Rheumatology • Vitiligo • CTLA4

O07 Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (PubMed, Br J Dermatol) - "Inclusion criteria were adults who received at least one of the biologics, apremilast or conventional nonbiologics (acitretin, ciclosporin and methotrexate) for ≥ 6 months. All biologics licensed for psoriasis were analysed except for infliximab, which had higher prescription criteria...The certolizumab group had a low mean age of 37.4 years (SD 10.3), the ustekinumab group had a significantly longer median treatment duration of over 4 years (IQR 1.83-6.73), and more patients in the ixekizumab (42.6%) and certolizumab (40.6%) groups had concomitant psoriatic arthritis...IRs (95% CIs) of other tumour necrosis factor-α inhibitors were 15.7 (14.5-17.1) for adalimumab and 16.7 (13.8-20.0) for etanercept. For interleukin-17 inhibitors the IRs (95% CIs) were 18.4 (15.9-21.2) for secukinumab, 7.63 (0.92-27.6) for bimekizumab, 14.5 (7.73-24.8) for brodalumab and 18.5 (14.0-24.0) for ixekizumab. For interleukin-23 inhibitors the IRs (95% CIs) were 13.5 (9.97-17.8) for guselkumab,..."

Journal • Observational data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the AURORA Study, Including the ANZIBD Consortium. (PubMed, JGH Open) - "The addition of an immunomodulator did not significantly impact outcomes. Ustekinumab was found to be safe in most patients."

Journal • Real-world evidence • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

CPC08 Acrodermatitis enteropathica in adulthood secondary to acquired zinc deficiency: a diagnostic challenge. (PubMed, Br J Dermatol) - "The patient was treated for psoriasis with ustekinumab; however, this worsened her existing rash, with the skin lesions taking on an annular, polycyclic appearance with desquamation...We present a case of acrodermatitis enteropathica in an adult patient with acquired zinc deficiency masking as psoriasis. This case highlights an important differential to consider in patients with suspected psoriasis not responding to conventional treatments."

Journal • Atopic Dermatitis • Cardiovascular • CNS Disorders • Coronary Artery Disease • Cutaneous Lupus Erythematosus • Dermatitis • Dermatology • Dermatopathology • Epilepsy • Heart Failure • Immunology • Inflammatory Arthritis • Lupus • Movement Disorders • Oncology • Psoriasis

P091 Posterior reversible encephalopathy syndrome (PRES) presenting in a patient with psoriasis receiving ustekinumab. (PubMed, Br J Dermatol) - P3 | "Prochlorperazine 5 mg three times daily and amlodipine 10 mg once daily were commenced and ustekinumab suspended...PRES has been described in patients using adalimumab, infliximab and ustekinumab, most commonly in the context of inflammatory bowel disease...However, it is important that clinicians are aware of this rare debilitating neurological adverse event, so prompt withdrawal of possible triggers including biologic agents can be made to facilitate neurological recovery. The half-life of ustekinumab is problematic for prompt withdrawal and there remain questions regarding ongoing management of the patient's inflammatory dermatosis and arthritis, as case reports document worsening of PRES on reintroduction of traditional immunosuppressive systemic agents."

Journal • Cardiovascular • CNS Disorders • Dermatology • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

PA12 Evaluating how we manage our paediatric patients with eczema and psoriasis with systemic agents, and identifying barriers to research registry recruitment. (PubMed, Br J Dermatol) - "We identified 42 paediatric patients treated with a systemic for their eczema (n = 34) or psoriasis (n = 8), which included methotrexate (n = 20), dupilumab (n = 18), adalimumab (n = 3) and ustekinumab (n = 1). Failure to inform patients about research registries has also been identified as a barrier to enrolment, with feedback from patient guardian interviews overwhelmingly positive regarding willingness to enrol. Increased education and promotion of these registries is clearly paramount to increasing recruitment."

Journal • Retrospective data • Atopic Dermatitis • Dermatology • Immunology • Pediatrics • Psoriasis

Efficacy of Advanced Therapies as Prophylaxis and for Active Disease in Postoperative Crohn's Disease: A Comprehensive Review. (PubMed, J Clin Med) - "Infliximab and vedolizumab have the strongest evidence for preventing endoscopic recurrence in postoperative Crohn's disease. Adalimumab and ustekinumab are viable alternatives supported by observational and post hoc trial data...Approaches that integrate disease location, clinical risk profiles, and knowledge of underlying immunopathogenic pathways could provide more precise clinical guidance. Finding molecular predictors of recurrence, directly comparing cutting-edge treatments, and integrating precision medicine techniques into standard postoperative care should be the main priorities of future research."

Journal • Review • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • IL23A

Risankizumab is effective following ustekinumab failure in Crohn's disease: A real-world study from a tertiary center. (PubMed, World J Gastrointest Pharmacol Ther) - "Switching from ustekinumab to risankizumab in active CD led to significant clinical and biochemical improvements and high remission rates, particularly in patients with SLOR. These findings support risankizumab as an effective option following ustekinumab failure in refractory CD."

Journal • Real-world evidence • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • CRP • IL12A

Risk of Incident Immune-Mediated Inflammatory Diseases with Second Tumor Necrosis Factor Inhibitor Versus Alternative Biologic Therapy in Patients with Inflammatory Bowel Disease and First TNFi Exposure: A Real-World Cohort Study. (PubMed, Dig Dis Sci) - "In this large real-world IBD cohort with exposure to a TNFi, second TNFi use was associated with a higher risk of de-novo IMIDs compared to ustekinumab or vedolizumab."

Journal • Real-world evidence • Ankylosing Spondylitis • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis

The Association Between TNFSF4 Polymorphism and CD (clinicaltrials.gov) - P=N/A | N=818 | Completed | Sponsor: Second Affiliated Hospital of Wenzhou Medical University

New trial • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

An evaluation of guselkumab for the treatment of ulcerative colitis. (PubMed, Expert Opin Biol Ther) - "No direct comparisons are available between individual IL-23 antagonists or with ustekinumab, the IL-12/23 antagonist, which limits decision-making in clinical practice. Combining two biologics as advanced combination treatment is an attractive strategy to break the therapeutic efficacy ceiling in UC - a proof-of-concept phase 2 trial combining guselkumab and golimumab has shown promise, the combination is currently undergoing evaluation in a larger ongoing trial."

Journal • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A • IL23A

Five-year effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. (PubMed, Clin Res Hepatol Gastroenterol) - "In this study, ustekinumab was associated with higher rate of steroid-free clinical remission and treatment persistence than vedolizumab after 5 years of follow-up, particularly in patients with ileal CD, stricturing or penetrating behaviour and history of CD-related intestinal surgery."

Journal • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • Oncology

Relationship between plasma concentrations of ustekinumab at week 8 and its effectiveness in patients with Crohn's disease. (PubMed, Farm Hosp) - "This study confirms the association between ustekinumab concentrations at week 8 and treatment effectiveness in Crohn's disease. A concentration >13.29 μg/mL at week 8 was identified as a predictive marker of biochemical remission at week 24, which could serve as a basis for future therapeutic decision-making algorithms."

Journal • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • Oncology

High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study. (PubMed, Scand J Gastroenterol) - "Endoscopic remission (absence of ulcers in CD and endoscopic Mayo ≤1 in UC) was observed in 58.3% of patients. First-line treatment with ustekinumab demonstrates high treatment-persistence and is associated with substantial rates of clinical, biochemical, and endoscopic remission in patients with IBD."

Journal • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

From reactive to predictive: Advancing biologic dosing in dermatology. (PubMed, J Eur Acad Dermatol Venereol) - "Model-informed precision dosing represents a paradigm shift in biologic therapy management, moving from standardised to dynamic, patient-centric dosing. By combining real-time monitoring, digital tools, and biological profiling, MIPD has the potential to maximise clinical response, minimise toxicity, and enhance the sustainability of long-term biologic treatment in dermatology."

Journal • Review • Dermatology • Immunology

Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. (PubMed, Ann Med) - "Interleukin (IL)-23 inhibitors-including IL-23p19 inhibitors (guselkumab, mirikizumab, risankizumab) and the IL-12/23p40 inhibitor ustekinumab-are emerging treatments for Crohn's disease (CD), but comparative data among them remain limited. This is the first NMA comparing IL-23 inhibitors using contemporary evidence. The results offer practical insights for personalized CD treatment: guselkumab may be preferred for rapid response, mirikizumab for safety, and risankizumab for balanced efficacy."

Clinical • Journal • Retrospective data • Review • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • IL12A • IL23A

Comparative effectiveness of ixekizumab versus ustekinumab in patients with psoriasis: an RCT replication using data from an observational study (SPEECH). (PubMed, Value Health) - "The results of IXORA-S were successfully replicated using real-world data from SPEECH. This demonstrates that registry-based observational data can yield reliable estimates of treatment effects and may be used to investigate effectiveness questions not feasible to study in randomized trials, such as long-term outcomes and effects in underrepresented populations."

HEOR • Journal • Observational data • Dermatology • Immunology • Psoriasis

Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East. (PubMed, Crohns Colitis 360) - "In AT-exposed patients, prior ustekinumab exposure was associated with lower remission rates (OR 0.11, P = .021) and a higher likelihood of dose intensification (OR 5.67, P = .045). No new safety signals were identified. This first Middle Eastern real-world study confirms risankizumab is effective and safe for complex CD and supports its use across different treatment lines."

Journal • Real-world evidence • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • CRP • IL23A

Time to lift the moratorium on IL-23 inhibitors for axial psoriatic arthritis. (PubMed, Lancet Rheumatol) - "However, post-hoc analyses of clinical trials show clinical improvements in axial psoriatic arthritis following treatment with ustekinumab, guselkumab, and risankizumab...Furthermore, inadequate response to biological therapies in axial spondyloarthritis was associated with absence of MRI-determined bone marrow oedema, whereas responses to secukinumab in axial spondyloarthritis were independent of bone marrow oedema, pointing to divergent pathophysiological processes. The growing recognition of clinical, microanatomical, and immunological differences between axial spondyloarthritis and axial psoriatic arthritis suggests differential IL-23 pathway dependence. This Personal View aims to provide a deeper examination of these distinctions as a basis to propose reconsidering the current moratorium on IL-23 inhibitors-particularly in phenotypes not linked to HLA-B27-and to potentially expand therapeutic options."

Journal • Review • Ankylosing Spondylitis • Immunology • Inflammation • Inflammatory Arthritis • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • CRP • IL23A

Characterization of Laboratory Studies and Treatments of Interstitial Granulomatous Dermatitis with Arthritis: A Case Report and Review of the Literature (ISDS 2025) - "Methotrexate and hydroxychloroquine were each used in 20% of cases, and biologics were used in 8% of cases. The biologics utilized include adalimumab, infliximab, ustekinumab, and tocilizumab. Response to biologics was overall favorable, with cutaneous symptoms improving to a greater degree than arthralgias."

Case report • Clinical • Review • Dermatitis • Dermatology • Immunology • Inflammatory Arthritis • Musculoskeletal Pain • Rheumatoid Arthritis • Rheumatology • CRP

Utilisation and real-world effectiveness of advanced therapies for inflammatory bowel disease in Middle Eastern populations: a systematic review. (PubMed, BMJ Open Gastroenterol) - "Advanced therapies for IBD appear to be effective in Middle Eastern cohorts; however, the available evidence is methodologically diverse, with substantial heterogeneity in study design, population characteristics and outcome reporting, which limits the ability to draw strong conclusions and highlights the need for further robust evaluation. Prospective, collaborative regional registries are imperative to address these gaps and inform local guidelines."

Journal • Real-world evidence • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Pediatrics • Ulcerative Colitis

BOOSTERS: Biologics in Folliculitis Decalvans : an Adaptative Trial Research (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris

New P2 trial

Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT. (PubMed, Dermatol Ther (Heidelb)) - P3 | "Bimekizumab provided greater improvements in PROs versus comparators, with durable effects over 4 years. These findings reinforce bimekizumab's role in effective psoriasis management, linking clinical efficacy with sustained patient-reported benefits."

Journal • Dermatology • Immunology • Pain • Psoriasis

Predicting localized inflammation at skin sites in psoriasis using cell-cell interactions and gene expression profiles inferred from spatial transcriptomic data (ISDS 2025) - P2 | "In this study, we develop a statistical model that integrates both modalities to predict local tissue inflammation in skin biopsy sites from patients with plaque psoriasis treated with ustekinumab during the ITN PAUSE clinical trial (NCT01999868)...The model is then applied to treated-lesional samples at later time points to predict patch-wise disease severity. This framework illustrates how combining spatial statistics with transcriptomic features can yield predictive insights into disease dynamics and therapeutic response at the tissue microdomain level in psoriasis."

Gene expression profiling • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis